AIMS/HYPOTHESIS: Overexpression of the gene encoding phosphoprotein enriched in astrocytes 15 (PEA15), also known as phosphoprotein enriched in diabetes (PED), causes insulin resistance and diabetes in transgenic mice and has been observed in type 2 diabetic individuals. The aim of this study was to investigate whether PEA15 overexpression occurs in individuals at high risk of diabetes and whether it is associated with specific type 2 diabetes subphenotypes. SUBJECTS AND METHODS: We analysed PEA15 expression in euglycaemic first-degree relatives (FDR) of type 2 diabetic subjects. RESULTS: The expression of PEA15 in peripheral blood leucocytes (PBLs) paralleled that in fat and skeletal muscle tissues. In PBLs from the FDR, PEA15 expression was two-fold higher than in euglycaemic individuals with no family history of diabetes (control subjects), both at the protein and the mRNA level (p < 0.001). The expression of PEA15 was comparable in FDR and type 2 diabetic subjects and in each group close to one-third of the subjects expressed PEA15 levels more than 2 SD higher than the mean of control subjects. Subjects with IFG with at least one type 2 diabetes-affected FDR also overexpressed PEA15 (p < 0.05). In all the groups analysed, PEA15 expression was independent of sex and unrelated to age, BMI, waist circumference, systolic and diastolic BP, and fasting cholesterol, triacylglycerol and glucose levels. However, in euglycaemic FDR of type 2 diabetic subjects, PEA15 expression was inversely correlated with insulin sensitivity (r = -557, p = 0.01). CONCLUSIONS/ INTERPRETATION: We conclude that PEA15 overexpression represents a common defect in FDR of patients with type 2 diabetes and is correlated with reduced insulin sensitivity in these individuals.
AIMS/HYPOTHESIS: Overexpression of the gene encoding phosphoprotein enriched in astrocytes 15 (PEA15), also known as phosphoprotein enriched in diabetes (PED), causes insulin resistance and diabetes in transgenic mice and has been observed in type 2 diabetic individuals. The aim of this study was to investigate whether PEA15 overexpression occurs in individuals at high risk of diabetes and whether it is associated with specific type 2 diabetes subphenotypes. SUBJECTS AND METHODS: We analysed PEA15 expression in euglycaemic first-degree relatives (FDR) of type 2 diabetic subjects. RESULTS: The expression of PEA15 in peripheral blood leucocytes (PBLs) paralleled that in fat and skeletal muscle tissues. In PBLs from the FDR, PEA15 expression was two-fold higher than in euglycaemic individuals with no family history of diabetes (control subjects), both at the protein and the mRNA level (p < 0.001). The expression of PEA15 was comparable in FDR and type 2 diabetic subjects and in each group close to one-third of the subjects expressed PEA15 levels more than 2 SD higher than the mean of control subjects. Subjects with IFG with at least one type 2 diabetes-affected FDR also overexpressed PEA15 (p < 0.05). In all the groups analysed, PEA15 expression was independent of sex and unrelated to age, BMI, waist circumference, systolic and diastolic BP, and fasting cholesterol, triacylglycerol and glucose levels. However, in euglycaemic FDR of type 2 diabetic subjects, PEA15 expression was inversely correlated with insulin sensitivity (r = -557, p = 0.01). CONCLUSIONS/ INTERPRETATION: We conclude that PEA15 overexpression represents a common defect in FDR of patients with type 2 diabetes and is correlated with reduced insulin sensitivity in these individuals.
Authors: R L Hanson; R E Pratley; C Bogardus; K M Narayan; J M Roumain; G Imperatore; A Fagot-Campagna; D J Pettitt; P H Bennett; W C Knowler Journal: Am J Epidemiol Date: 2000-01-15 Impact factor: 4.897
Authors: J W Ramos; P E Hughes; M W Renshaw; M A Schwartz; E Formstecher; H Chneiweiss; M H Ginsberg Journal: Mol Biol Cell Date: 2000-09 Impact factor: 4.138
Authors: D Kitsberg; E Formstecher; M Fauquet; M Kubes; J Cordier; B Canton; G Pan; M Rolli; J Glowinski; H Chneiweiss Journal: J Neurosci Date: 1999-10-01 Impact factor: 6.167
Authors: Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov Journal: Proc Natl Acad Sci U S A Date: 2005-09-30 Impact factor: 11.205
Authors: G Condorelli; G Vigliotta; A Trencia; M A Maitan; M Caruso; C Miele; F Oriente; S Santopietro; P Formisano; F Beguinot Journal: Diabetes Date: 2001-06 Impact factor: 9.461
Authors: Pietro Formisano; Giuseppe Perruolo; Silvana Libertini; Stefania Santopietro; Giancarlo Troncone; Gregory Alexander Raciti; Francesco Oriente; Giuseppe Portella; Claudia Miele; Francesco Beguinot Journal: Oncogene Date: 2005-10-27 Impact factor: 9.867
Authors: S Savastano; R Valentino; G Pizza; A De Rosa; F Orio; F Passaretti; P Formisano; G Lombardi; F Beguinot; A Colao Journal: J Endocrinol Invest Date: 2010 Jul-Aug Impact factor: 4.256
Authors: P Ungaro; R Teperino; P Mirra; M Longo; M Ciccarelli; G A Raciti; C Nigro; C Miele; P Formisano; F Beguinot Journal: Diabetologia Date: 2010-04-16 Impact factor: 10.122
Authors: F Oriente; S Iovino; A Cassese; C Romano; C Miele; G Troncone; M Balletta; A Perfetti; G Santulli; G Iaccarino; R Valentino; F Beguinot; P Formisano Journal: Diabetologia Date: 2009-09-30 Impact factor: 10.122
Authors: Fabio Panariello; Giuseppe Perruolo; Angela Cassese; Ferdinando Giacco; Ginevra Botta; Alessia P M Barbagallo; Giovanni Muscettola; Francesco Beguinot; Pietro Formisano; Andrea de Bartolomeis Journal: J Cell Physiol Date: 2012-04 Impact factor: 6.384